28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Conference

Scholarly Activity

related documents

A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226) Conferences
Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221 Conferences